|Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals|
A Gonzalez-Serna, JE Min, C Woods, D Chan, VD Lima, JSG Montaner, ...
Clinical infectious diseases 58 (8), 1165-1173, 2014
|HIV drug resistance detected during low-level viremia is associated with subsequent virologic failure|
LC Swenson, JE Min, CK Woods, E Cai, JZ Li, JSG Montaner, ...
AIDS (London, England) 28 (8), 1125, 2014
|Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers|
MC Romero-Sánchez, A González-Serna, YM Pacheco, ...
Journal of Infection 65 (5), 431-438, 2012
|Correlation between the Trofile® test and virological response to a short-term maraviroc exposure in HIV-infected patients|
M Genebat, E Ruiz-Mateos, JA Leon, A Gonzalez-Serna, I Pulido, I Rivas, ...
Journal of antimicrobial chemotherapy 64 (4), 845-849, 2009
|TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches|
A Gonzalez-Serna, M Leal, M Genebat, MA Abad, A Garcia-Perganeda, ...
Journal of clinical microbiology 48 (12), 4453-4458, 2010
|Temporal trends in the discontinuation of first-line antiretroviral therapy|
A Gonzalez-Serna, K Chan, B Yip, W Chau, R McGovern, H Samji, ...
Journal of Antimicrobial Chemotherapy 69 (8), 2202-2209, 2014
|Effect of maraviroc on HIV disease progression-related biomarkers|
MC Romero-Sánchez, K Machmach, A Gonzalez-Serna, M Genebat, ...
Antimicrobial agents and chemotherapy 56 (11), 5858-5864, 2012
|Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods|
A Gonzalez-Serna, RA McGovern, PR Harrigan, F Vidal, AFY Poon, ...
Antimicrobial agents and chemotherapy 56 (3), 1202-1207, 2012
|Rapid decrease in peripheral blood mononucleated cell telomere length after HIV seroconversion, but not HCV seroconversion|
A Gonzalez-Serna, A Ajaykumar, I Gadawski, MA Muñoz-Fernández, ...
Journal of acquired immune deficiency syndromes (1999) 76 (1), e29, 2017
|Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice|
M Genebat, E Ruiz-Mateos, I Pulido, A González-Serna, ...
Current HIV research 8 (6), 482-486, 2010
|A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure|
A Gonzalez-Serna, LC Swenson, B Watson, W Zhang, A Nohpal, ...
Clinical Microbiology and Infection 22 (12), 1004. e9-1004. e16, 2016
|Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI …|
MC Romero-Sánchez, AI Álvarez-Ríos, E Bernal-Morell, M Genebat, ...
Antiviral research 111, 26-32, 2014
|Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors|
E Ruiz-Mateos, A González-Serna, M Genebat, K Machmach, F Vidal, ...
Antimicrobial agents and chemotherapy 55 (10), 4664-4669, 2011
|Discordance rates between Trofile® test and short-term virological response to maraviroc|
M Genebat, E Ruiz-Mateos, A González-Serna, I Pulido, ...
Antiviral research 89 (2), 182-185, 2011
|HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients|
A Gonzalez-Serna, MC Romero-Sánchez, S Ferrando-Martinez, ...
Antimicrobial agents and chemotherapy 56 (7), 3981-3983, 2012
|CD8 TCR β chain repertoire expansions and deletions are related with immunologic markers in HIV-1-infected patients during treatment interruption|
A González-Serna, M Abad-Fernández, N Soriano-Sarabia, M Leal, ...
Journal of Clinical Virology 58 (4), 703-709, 2013
|Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens|
A Gonzalez-Serna, S Ferrando-Martinez, L Tarancon-Diez, ...
Journal of translational medicine 15 (1), 1-10, 2017
|High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment|
J Macías, A Pinilla, FA Lao-Dominguez, A Corma, E Contreras-Macias, ...
Scientific reports 10 (1), 1-6, 2020
|Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment|
M Genebat, I Pulido, MC Romero-Sánchez, A González-Serna, ...
Antiviral research 95 (3), 207-211, 2012
|Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy|
PD Juan Macías, MD, MD Paz González-Moreno, ...
medRxiv 20104141 (https://doi.org/10.1101/2020.05.16.2010), 20104141, 2020